{
    "clinical_study": {
        "@rank": "58595", 
        "brief_summary": {
            "textblock": "Data collection on the safety and efficacy of Zarzio\u00ae / Filgrastim HEXAL\u00ae in adult healthy\n      unrelated stem cell donors undergoing peripheral blood progenitor cell mobilization."
        }, 
        "brief_title": "Non-interventional, Long-term Safety Data Collection of Zarzio\u00ae / Filgrastim HEXAL\u00ae in Stem Cell Donors", 
        "completion_date": {
            "#text": "December 2024", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Blood Progenitor Cell Mobilization With G-CSF", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  none\n\n        Exclusion Criteria:\n\n          -  Related to recipient\n\n          -  Chronic significant organ diseases\n\n          -  Systemic autoimmune diseases\n\n          -  Chronic infectious diseases\n\n          -  History of malignant disease\n\n          -  Pregnant and breastfeeding women\n\n          -  Hypersensitivity to E. coli derived proteins\n\n          -  Hypersensitivity to the active substance or to any of the excipients of the\n             Sandoz' filgrastim\n\n          -  Absolute and relative contraindications as specified in the summary of product\n             characteristics of  the Sandoz` filgrastim\n\n          -  Participation in previous stem cell mobilization procedures\n\n          -  Previous or concurrent use of other mobilising agents, e.g. plerixafor\n\n          -  Donor is unwilling to give written informed consent to his/her study participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "adult, unrelated, healthy volunteers who received at least one dose of Sandoz' filgrastim"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766934", 
            "org_study_id": "EP06-501"
        }, 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peripheral blood progenitor cell (PBPC) mobilization", 
            "allogenic hematopoetic stem cell transplantation (HSCT)", 
            "recombinant human granulocyte colony stimulating factor (rhG-CSF)", 
            "filgrastim"
        ], 
        "lastchanged_date": "January 16, 2013", 
        "location": {
            "contact": {
                "last_name": "Halvard B\u00f6nig, Dr.med. M.A., MD"
            }, 
            "facility": {
                "address": {
                    "city": "Frankfurt/Main", 
                    "country": "Germany", 
                    "state": "Hessen", 
                    "zip": "60528"
                }, 
                "name": "German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio\u00ae / Filgrastim HEXAL\u00ae in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization", 
        "overall_contact": {
            "last_name": "Sandoz", 
            "phone": "+49 8024 476", 
            "phone_ext": "0"
        }, 
        "overall_official": [
            {
                "affiliation": "Blood Donor Service Baden-Wuerttemberg Hessen", 
                "last_name": "Halvard B\u00f6nig, Dr. med, M.A., MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Blood Donor Service Baden-Wuerttemberg Hessen", 
                "last_name": "Halvard B\u00f6nig, Dr. med. M.A., MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2024", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to investigate adverse events that are suspected to be related to stem cell mobilization with the Sandoz' filgrastim in healthy unrelated donors.", 
            "measure": "Incidence of drug-related adverse events following mobilization with Sandoz' filgrastim.", 
            "safety_issue": "No", 
            "time_frame": "each patient will be followed for 10 years after mobilization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766934"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary objective is to investigate the efficacy of stem cell mobilization with the Sandoz' filgrastim in terms of the CD34+ cell count.", 
            "measure": "Efficacy assessment in terms of the CD34+ cell count.", 
            "safety_issue": "No", 
            "time_frame": "CD34+ cells are counted on 1 day immediately preceding apheresis"
        }, 
        "source": "Sandoz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}